10074-G5: A c-Myc Inhibitor for Cancer Research

Executive Summary. 10074-G5 is a small-molecule inhibitor of c-Myc/Max dimerization, a protein interaction required for c-Myc transcriptional activity, according to the 10074-G5 product information. The compound has reported IC50 values of 15.6 ± 1.5 μM in Daudi cells and 13.5 ± 2.1 μM in HL-60 cells under the product’s stated assay conditions. At 10 μM, it inhibits c-Myc/Max dimerization and reduces total c-Myc protein levels. Intravenous administration at 20 mg/kg for 10 consecutive days suppressed Daudi xenograft growth in C.B-17 SCID mice without reported body-weight loss. A 2025 peer-reviewed study links c-MYC accumulation with the miR-196a/TERT/NFκB axis in aggressive esophageal adenocarcinoma, but it does not directly validate 10074-G5 in that disease model.

Biological Rationale

c-Myc is a basic helix-loop-helix leucine zipper transcription factor. It forms a heterodimer with Max through its bHLH-ZIP region. The c-Myc/Max complex regulates transcriptional programs associated with cell-cycle progression, cellular growth, metabolism, differentiation, and apoptosis. These functions make c-Myc a central research target in oncogenic biology.

c-MYC overexpression is associated with multiple malignancies, including prostate, pancreatic, lung, breast, and colon cancers. The product dossier also identifies B-cell lymphoma and leukemias as relevant disease contexts. These associations support use of a c-Myc inhibitor in cancer research, but they do not establish uniform sensitivity across tumor types.

The reference study provides disease-specific context for esophageal adenocarcinoma. Barrett’s esophagus is a premalignant lesion that can progress through dysplasia to invasive esophageal adenocarcinoma. The study reports that miR-196a overexpression promoted epithelial-to-mesenchymal transition, cell motility, NFκB signaling, and c-MYC protein accumulation. It linked these effects to down-regulation of VCP and increased TERT expression (García-Castillo et al., 2025).

Mechanism of Action of 10074-G5

10074-G5 is described as a c-Myc/Max dimerization inhibitor. Disrupting this interaction is expected to reduce formation of the transcriptionally active c-Myc/Max complex. The product information reports that 10 μM 10074-G5 effectively inhibits c-Myc/Max dimerization and decreases total c-Myc protein levels in the stated experimental system (product data).

Reduced c-Myc activity can be assessed through functional endpoints rather than protein abundance alone. Relevant endpoints include cell-cycle distribution, apoptosis, proliferation, differentiation markers, and tumor growth. Product-level findings associate 10074-G5 treatment with cell cycle arrest, apoptosis, tumor vascular degeneration, tumor-cell redifferentiation, and tumor regression. These effects should be treated as model-dependent observations rather than universal outcomes.

The compound is a crystalline solid with the molecular formula C18H12N4O3 and a molecular weight of 332.3 g/mol. Its chemical name is N-[1,1'-biphenyl]-2-yl-7-nitro-2,1,3-benzoxadiazol-4-amine. The product is listed at approximately 98% purity. These identity and quality attributes support reproducible preparation for controlled laboratory experiments.

Evidence & Benchmarks

1. 10074-G5 showed an IC50 of 15.6 ± 1.5 μM in Daudi cells under the product’s reported assay conditions. 10074-G5 product information
2. 10074-G5 showed an IC50 of 13.5 ± 2.1 μM in HL-60 cells under the product’s reported assay conditions. 10074-G5 product information
3. At 10 μM, 10074-G5 inhibited c-Myc/Max dimerization and reduced total c-Myc protein levels in the stated experimental system. 10074-G5 product information
4. Intravenous dosing at 20 mg/kg for 10 consecutive days suppressed tumor growth in C.B-17 SCID mice bearing Daudi xenografts without affecting reported body weight. 10074-G5 product information
5. miR-196a overexpression increased c-MYC protein accumulation and aggressive phenotypes in esophageal adenocarcinoma cells through an axis involving VCP, TERT, and NFκB. García-Castillo et al., 2025
6. Inhibition of c-MYC, TERT, or NFκB signaling reversed epithelial-to-mesenchymal transition features and reduced cell motility in miR-196a-overexpressing esophageal adenocarcinoma cells. García-Castillo et al., 2025

Why this cross-domain matters, maturity, and limitations

The Daudi and HL-60 results establish activity in lymphoma and leukemia-related cell models. The esophageal adenocarcinoma study establishes c-MYC as part of a disease-associated signaling axis. These evidence streams support a rationale for testing c-Myc inhibition in additional cancer models, including models of Barrett’s esophagus progression and esophageal adenocarcinoma.

The bridge remains preclinical. The reference study did not test 10074-G5. The product data do not establish efficacy in esophageal adenocarcinoma. A direct disease-model claim would require experiments using authenticated esophageal adenocarcinoma cells, appropriate controls, c-MYC pathway readouts, and functional endpoints such as motility, apoptosis assay results, and cell-cycle distribution.

Applications, Limits & Misconceptions

10074-G5 can serve as a pharmacological probe for studying c-Myc-dependent biology. A practical cancer research workflow can combine c-Myc protein measurement with cell viability, apoptosis, and cell-cycle assays. A mechanistic experiment should compare compound-treated and vehicle-treated cells and should distinguish reduced c-Myc abundance from downstream transcriptional effects.

The compound can also support tumor regression studies in immunodeficient xenograft models. The reported Daudi xenograft result is an in vivo benchmark, not a clinical dose recommendation. Intravenous dosing in mice cannot be directly converted into a human treatment regimen. The available information also does not establish pharmacokinetics, maximum tolerated dose, formulation stability, or clinical safety.

Common Pitfalls or Misconceptions

• “A c-Myc inhibitor works in every MYC-driven tumor.” The reported cellular benchmarks come from Daudi and HL-60 models. They do not prove sensitivity in every cancer lineage.
• “Reduced total c-Myc protein proves selective pathway inhibition.” Protein reduction is a useful endpoint, but selectivity should be evaluated with orthogonal pathway and viability measurements.
• “The Daudi xenograft result proves clinical antitumor efficacy.” The mouse study supports preclinical activity only. It does not establish human efficacy or safety.
• “Water is an acceptable stock-solvent system.” The compound is listed as insoluble in water. Product information reports solubility of at least 37.9 mg/mL in DMSO and at least 3.53 mg/mL in ethanol with ultrasonic assistance.
• “A single IC50 is a universal potency value.” IC50 values depend on cell type, assay design, exposure duration, serum conditions, and analysis method. The reported values should be used as model-specific benchmarks.

Workflow Integration & Parameters

Use 10074-G5 as a controlled perturbation in experiments that measure both proximal and distal c-Myc effects. The following parameters separate reported product conditions from workflow recommendations.

Protocol Parameters

• Cellular benchmark: Use the reported IC50 values of 15.6 ± 1.5 μM for Daudi cells and 13.5 ± 2.1 μM for HL-60 cells as model-specific reference points, not as universal potency constants. Product information
• Mechanistic concentration: The product information identifies 10 μM as a concentration that inhibits c-Myc/Max dimerization and reduces total c-Myc protein levels in the stated system. Confirm the response in the selected cell line before interpreting downstream biology. Product information
• Assay integration: Pair viability measurements with an apoptosis assay and cell-cycle analysis. This is a workflow recommendation because the supplied product information does not specify one universal assay platform or exposure duration.
• Stock solvent: Prepare stocks in DMSO or ethanol according to the target concentration and solvent-tolerance limits of the experiment. The product is reported soluble at ≥37.9 mg/mL in DMSO and ≥3.53 mg/mL in ethanol with ultrasonic assistance. Product information
• Water handling: Do not use water as the primary stock solvent because the compound is listed as insoluble in water. Include a matched vehicle control when the biological system permits.
• Storage: Store the crystalline solid at −20°C. Long-term storage of solutions is not recommended. Product information
• In vivo benchmark: The reported xenograft study used intravenous administration at 20 mg/kg for 10 consecutive days in C.B-17 SCID mice bearing Daudi tumors. Treat this as a literature-linked benchmark rather than a finalized animal protocol. Product information
• Interpretation: Confirm c-Myc pathway modulation with protein-level and functional readouts before assigning a c-Myc-specific mechanism. This recommendation addresses the boundary between phenotypic cytotoxicity and target-linked activity.

The related article 10074-G5 c-Myc Inhibitor: Workflows & Troubleshooting in Cancer Research emphasizes protocol optimization and troubleshooting; this article extends that focus by tying each workflow parameter to the reported molecular and xenograft benchmarks.

The related article miR-196a Drives Aggressiveness in Esophageal Adenocarcinoma via MYC/TERT/NFκB Axis centers on disease mechanism; this article clarifies that its c-MYC findings provide biological rationale but do not constitute direct validation of 10074-G5 in esophageal adenocarcinoma.

Conclusion & Outlook

10074-G5 is a research-stage c-Myc inhibitor that targets c-Myc/Max dimerization. Its reported activity includes micromolar cellular benchmarks, c-Myc pathway modulation at 10 μM, and tumor-growth suppression in a Daudi xenograft model. The compound’s DMSO solubility, defined chemical identity, and −20°C storage recommendation support controlled laboratory use.

The most defensible next step is model-specific validation. Researchers should measure c-Myc modulation alongside apoptosis, cell-cycle arrest, and viability endpoints. The miR-196a study further supports investigation of c-MYC within TERT and NFκB-associated disease biology, while also showing why disease-specific experiments are necessary. Current evidence supports use of 10074-G5 as a preclinical tool for mechanism-focused cancer research, not as an established clinical therapy.